Department of Health and Human Services October 2020 – Federal Register Recent Federal Regulation Documents

Statement of Organizations, Functions, and Delegations of Authority. The Administration for Children and Families (ACF) is restructuring the Office on Trafficking in Persons (OTIP) within the Office of the Assistant Secretary for Children and Families, ACF, into three divisionsPrevention, Protection, and Research and Policythat report to the OTIP Director.

HRSA has decided not to provide funding for HRSA-20-083 Quality Improvement Solutions for Sustained Epidemic Control Project, supported by the President's Emergency Plan for AIDS Relief (PEPFAR).

In accordance with the Federal Advisory Committee Act, HHS is hereby giving notice that the Council on Graduate Medical Education (COGME) has been rechartered. The effective date of the renewed charter is September 30, 2020.

The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this notice to Senti Biosciences, Inc. (``Senti'') located in South San Francisco, CA.

The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research and development.

The Department of Health and Human Services (HHS) notifies federal agencies of the laboratories and Instrumented Initial Testing Facilities (IITFs) currently certified to meet the standards of the Mandatory Guidelines for Federal Workplace Drug Testing Programs using Urine or Oral Fluid (Mandatory Guidelines).

The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled ``The Use of Physiologically Based Pharmacokinetic AnalysesBiopharmaceutics Applications for Oral Drug Product Development, Manufacturing Changes, and Controls.'' This guidance provides general recommendations regarding the development, evaluation, and use of physiologically based pharmacokinetic (PBPK) analyses for biopharmaceutics applications employed by sponsors of investigational new drug applications, new drug applications, or abbreviated new drug applications, and supplements to these applications, for oral drug product development, manufacturing changes, and controls. The guidance covers how to develop, evaluate, and apply PBPK models for biopharmaceutics-related uses, such as establishing clinically relevant dissolution specifications and quality risk assessment for postapproval manufacturing changes.

The Secretary of Health and Human Services (Secretary) is issuing a final rule to implement a provision of the Federal Food, Drug, and Cosmetic Act (FD&C Act) to allow importation of certain prescription drugs from Canada. Under this final rule, States and Indian Tribes, and in certain future circumstances pharmacists and wholesalers, may submit importation program proposals to the Food and Drug Administration (FDA, the Agency, or we) for review and authorization. An importation program may be cosponsored by a State, Indian Tribe, pharmacist, or wholesaler. The final rule contains all requirements necessary for a sponsor to demonstrate that their importation program will pose no additional risk to the public's health and safety. In addition, the final rule requires that the sponsor explain how they will ensure their program will result in a significant reduction in the cost of covered products to the American consumer.